Novavax’s COVID-19 vaccine has been approved for use in Canadians age 18 and older by Health Canada.
The approval of the vaccine, known as Nuvaxovid, comes about 18 months after the federal government announced a deal to produce batches of it in Montreal.
Health Canada is recommending the interval for the two-dose vaccine to be at least 21 days based on evidence from clinical trials.
It’s not immediately clear how much of the vaccine will be supplied to Canada, which is well into its booster-dose campaign. The agency was holding a technical briefing early Thursday afternoon.
Trial data suggests the vaccine is more than
